If this box remains here for more than 30 seconds, click this link to try again.
Industries
Functions
Home » Products & Services » Best Practice Database » Product Launch » Market Entry: Metabolic and Cardiovascular Diseases
Download FREE Excerpt
11 Info Graphics
14 Data Graphics
110+ Metrics
7 Narratives
Single User: Authorizes use by the person who places the order or for whom the order was placed.
Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.
Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.
Buy Now
STUDY OVERVIEW
One of the more difficult aspects of planning a new cardiovascular product launch is balancing the different resource and investment allocations that are needed to prepare the marketplace for a new product. In particular, organizations wrestle with allocating the appropriate resources for informing key stakeholders as well as other critical launch activities that are carried out across different functional areas. This Best Practices, LLC study reviews key resource and investment benchmarks regarding a new cardiovascular product launch, such as percentage of resources for educating stakeholder groups, investment requirements for entering a competitive marketplace, and rating the importance of using launch resources for key activities carried out across different groups such as R&D, Medical Affairs, Marketing, Sales, and Supply Chain. In addition, the study also looks at current and future trends in resource allocation. Executives and managers in cardiovascular product launch groups can use this study to compare their current launch resource and allocation approaches with those at leading companies.
KEY TOPICS
SAMPLE METRICS
SAMPLE KEY FINDINGS
METHODOLOGY
The benchmark class includes participation from 44 executives at 38 leading pharmaceutical, biotech and health-care companies. Launch leaders in Metabolics and Cardiology represented the two largest therapeutic area segments to participate in this research project.
If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.
Top